Clinical Trials Sponsored by Sanofi-Regeneron

Total 3779 results

Sanofi
Regeneron Pharmaceuticals

Completed

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

Hypercholesterolemia

United States, Australia, Belgium, Canada, Denmark, Netherlands, New Zealand, Spain
Sanofi
Regeneron Pharmaceuticals

Completed

A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)

Rheumatoid Arthritis

Japan
Sanofi
Regeneron Pharmaceuticals

Completed

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous (SC) Administered Alirocumab in Healthy Chinese Subjects

Hypercholesterolemia

China
Regeneron Pharmaceuticals
Sanofi

Completed

A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects

Healthy Volunteers

Belgium
Sanofi
Regeneron Pharmaceuticals

Terminated

Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers

Rheumatoid Arthritis

United States, Italy, Mexico, Colombia, Czechia, Spain
Sanofi
Regeneron Pharmaceuticals

Terminated

An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate (RA-COMPARE)

Rheumatoid Arthritis

United States, Argentina, Australia, Brazil, Chile, Czechia, Finland, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Lithuania, Malaysia, Mexico, Peru, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine, F... and more
Sanofi
Regeneron Pharmaceuticals

Completed

An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

Asthma

Spain, United States, Chile, Australia, France, Mexico, Argentina, Italy, Japan, Poland, Russian Federation, South Africa, Turkey, Ukraine, Korea, Republic of, New Zealand
Sanofi
Regeneron Pharmaceuticals

Completed

To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA) (SARIL-RA-ONE)

Rheumatoid Arthritis

United States, Chile, Czechia, Estonia, Hungary, Poland, Russian Federation
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

Asthma

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Colorectal Cancer Metastatic (AFEQT)

Colorectal Cancer Metastatic

France
Sanofi
Regeneron Pharmaceuticals

Completed

A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy (AFLAME)

Colorectal Cancer Metastatic

Taiwan, China, Hong Kong, Japan, Singapore
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)

Hypercholesterolaemia

Netherlands, United States, Canada, Russian Federation, South Africa
Regeneron Pharmaceuticals
Sanofi

Completed

Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)

Atopic Dermatitis

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer

Neoplasms | Cancer of the Ovary

United States, France, Canada, Australia, Germany, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland
Sanofi
Regeneron Pharmaceuticals

Terminated

Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer (VANILLA)

Pancreatic Neoplasm

United States, France, Canada, Poland, Romania, Russian Federation, Germany, Italy, Spain, Switzerland, Bulgaria, India, Belgium, Czech Republic, Mexico, Argentina, Hungary, Colombia, Slovakia, Chile, Austria, Greece, Puerto Rico, Cyprus
Sanofi
Regeneron Pharmaceuticals

Completed

A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (VITAL)

Carcinoma | Non Small Cell Lung

United States, France, Canada, Brazil, Poland, Romania, Russian Federation, Germany, Italy, Netherlands, Portugal, Spain, Sweden, Bulgaria, Estonia, India, Malaysia, Singapore, Taiwan, Czech Republic, Argentina, Finland, Hungary, Korea... and more
Sanofi
Regeneron Pharmaceuticals

Completed

Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma

Lymphoma, Non-Hodgkin

France
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy (ODYSSEY FH I)

Hypercholesterolemia

United States, Austria, Canada, Czech Republic, Denmark, France, Israel, Netherlands, Norway, Russian Federation, South Africa, Spain, Sweden, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

Hypercholesterolemia

Sweden, Germany, Russian Federation, Denmark, Israel, South Africa, Spain, Hungary, United States, Colombia, Czech Republic, Argentina, Belgium, Bulgaria, Canada, Chile, Finland, France, Italy, Mexico, Netherlands, Norway, Poland, Por... and more
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia (ODYSSEY MONO)

Hypercholesterolemia

United States, Belgium, Finland, Netherlands
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)

Hypercholesterolemia

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy

Hypercholesterolemia

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Nesvacumab (REGN910/ SAR307746)

Solid Tumors

United States, Canada
Regeneron Pharmaceuticals
Sanofi

Completed

A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Single Ascending Dose Study of Safety and Tolerability of Sarilumab and Methotrexate in Japanese Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Japan
Sanofi
Regeneron Pharmaceuticals

Completed

Safety, Tolerability and Pharmacokinetics of SAR231893 (REGN668) in Healthy Japanese Adult Male Subjects

Healthy

Japan
Sanofi
Regeneron Pharmaceuticals

Completed

Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)

Hypercholesterolemia

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Ascending Dose Study of the Safety and Tolerability of REGN668(SAR231893) in Normal Healthy Volunteers

Healthy

United States
Sanofi
Regeneron Pharmaceuticals

Completed

AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites

Ovarian Neoplasms

United States, Italy, Sweden
Sanofi
Regeneron Pharmaceuticals

Completed

Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma

Neoplasms, Lung | Pulmonary Diseases

United States, France, Canada
Regeneron Pharmaceuticals
Sanofi

Completed

A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain

Sciatica

United States
Regeneron Pharmaceuticals
Sanofi

Withdrawn

Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Pain Resulting From Thermal Injury

Thermal Injury Pain

United States
Sanofi
Regeneron Pharmaceuticals

Not yet recruiting

Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain (PROADAP)

Atopic Dermatitis
Sanofi
Regeneron Pharmaceuticals

Recruiting

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

Bronchiectasis

Spain, United Kingdom, Israel, Japan, Turkey, Chile, United States, Canada, Denmark
Sanofi
Regeneron Pharmaceuticals

Recruiting

A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD (AERIFY-4)

Chronic Obstructive Pulmonary Disease

United States, Argentina, Bulgaria, Chile, China, Czechia, Hungary, Israel, Poland, Taiwan, Canada, Portugal, United Kingdom, Korea, Republic of, Japan, Slovakia, South Africa
Regeneron Pharmaceuticals
Sanofi

Recruiting

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

Hepatocellular Carcinoma | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma

United States
Regeneron Pharmaceuticals
Sanofi

Recruiting

Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma

Basal Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
Sanofi
Regeneron Pharmaceuticals

Recruiting

A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)

Juvenile Idiopathic Arthritis

Argentina, Bulgaria, Canada, Finland, France, Germany, Ireland, Italy, Russian Federation, Spain, United Kingdom
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

Atopic Dermatitis

United States, Canada, Czechia, Germany, Hungary, Poland, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Dupilumab in Japanese Patients With Atopic Dermatitis

Atopic Dermatitis

Japan
Sanofi
Regeneron Pharmaceuticals

Active, not recruiting

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation (NOTUS)

Chronic Obstructive Pulmonary Disease

Greece, Belgium, Spain, Argentina, Hungary, South Africa, United Kingdom, France, Latvia, Germany, Netherlands, Russian Federation, Ukraine, United States, Australia, Brazil, Bulgaria, Canada, Chile, Colombia, Czechia, Lithuania, Me... and more
Sanofi
Regeneron Pharmaceuticals

Active, not recruiting

Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD) (GLOBOSTAD)

Dermatitis Atopic

Spain, Czechia, Italy, Israel, Argentina, Australia, Austria, Belgium, Colombia, Finland, France, Greece, Japan, Kuwait, Mexico, Netherlands, Norway, Portugal, Russian Federation, Saudi Arabia, Taiwan, United Arab Emirates
Sanofi
Regeneron Pharmaceuticals

Completed

Dupilumab in CRSsNP (Liberty CRSsNP)

Chronic Sinusitis | Sinusitis | Chronic Rhinosinusitis Without Nasal Polyps | Sinus Disorder | Respiratory Disorder

Belgium, Spain, Argentina, Ukraine, Portugal, China, United States, Canada, Chile, Hungary, Korea, Republic of, Russian Federation, Sweden
Sanofi
Regeneron Pharmaceuticals

Completed

A Phase 4, Randomized, Double-blind, Placebo-controlled,Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma (MORPHEO)

Asthma

Spain, United States, Argentina, Canada, Germany, Italy, Netherlands, Portugal, Russian Federation, Ukraine, United Kingdom
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD) (PROSE)

Dermatitis, Atopic

United States, Canada
Sanofi
Regeneron Pharmaceuticals

Completed

A Study to Investigate the Pharmacokinetics (PK), Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants.

Healthy Volunteers

United States
Sanofi
Regeneron Pharmaceuticals

Completed

A Study to Investigate the Pharmacokinetics, Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants

Healthy Volunteer

United States
Sanofi
Regeneron Pharmaceuticals

Active, not recruiting

The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma (VESTIGE)

Asthma

Portugal, Ukraine, Spain, Taiwan, Sweden, United States, Bulgaria, Denmark, France, Italy, Romania, Saudi Arabia, United Kingdom
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE) (EoE KIDS)

Eosinophilic Esophagitis (EoE)

United States, Canada
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma

Asthma

China, India

Clinical Trials Sponsored by Sanofi-Regeneron

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations